相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Hereditary angioedema treatment goals have shifted from reducing attack frequency to achieving complete freedom from attacks with better quality of life. - Experts identify breakthrough attacks, severe or throat swelling, and life disruptions as signals to reassess preventive therapy in HAE. - Pregnancy and hormonal contraception require early HAE care team involvement, as estrogen is a known trigger and danazol is contraindicated. - Bradykinin-driven swelling in HAE does not respond to antihistamines, corticosteroids, or epinephrine, requiring specialized prescription medications.
- Techsomed received FDA 510(k) clearance to expand its BioTraceIO360 software platform for percutaneous ablation of soft tissue in the kidney, adding to its previously cleared liver application. - The AI-driven image-guided therapy platform enables physicians to plan and simulate ablation zones pre-procedure, guide procedures with quantitative feedback, and verify coverage for consistent outcomes. - This milestone advances Techsomed's vision for a unified multi-organ, hardware-agnostic platform that standardizes minimally invasive care from planning through verification. - The expansion addresses kidney cancer treatment needs, as the disease affects approximately 82,000 people in the United States annually.
- Despite high public interest in clinical trials, low participation rates are partly attributed to clinicians' lack of awareness and training in trial opportunities during fellowship programs. - Current barriers to clinical trial participation are particularly pronounced in underserved populations, highlighting the need for comprehensive education to promote equity in trial access. - Implementation of formal clinical trial curricula during fellowship can enhance patient care, advance cancer research, and strengthen patient-physician relationships in oncology practice.
